江苏浩欧博生物医药股份有限公司 审计报告及财务报表 二〇二四年度 = 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mk.gov.cn） 手作生息 【 江苏浩欧博生物医药股份有限公司 审计报告及财务报表 (2024 年 01 月 01 日至 2024 年 12 月 31 日止) | 目录 | 页次 | | --- | --- | | 审计报告 | 1-6 | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-90 | 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 审计报告 信会师报字[2025]第 ZA10173 号 江苏浩欧博生物医药股份有限公司全体股东: 一、审计意见 我们审计了江苏浩欧博生物医药股份有限公司(以下简称江苏浩 欧博)财务报表,包括 2024年1 ...

t = 10 元 ) | | | 期末余额 | 上年年末余额 | | --- | --- | --- | --- | | 流动资产: | | | | | 货币资金 | | 17,858,391.93 | 2,764,694.42 | | 交易性金融资产 | | | | | 衍生金融资产 | | | | | 应收票据 | | | | | 应收账款 | (二) | 19,073,011.98 | 14,126,115.21 | | 应收款项融资 | | | | | 预付款项 | (三) | 1,903,383.05 | 1,413,081.93 | | 其他应收款 | (四) | 219,183.00 | 27,146,868.29 | | 存货 | (元) | 1,307,657.23 | 246,435.37 | | 合同资产 | | | | | 持有待售资产 | | | | | 一年内到期的非流动资产 | (六) | 50,000.00 | 323,071.13 | | 其他流动资产 | (七) | 284 715.17 | | | 流动资产合计 | | 40,696,342.36 | 46,020,266 ...

根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规 定，江苏浩欧博生物医药股份有限公司（以下简称"公司"）董事会就公司在任 独立董事钱跃竑、肖强、黄蓉的独立性情况进行评估并出具如下专项意见： 经核查公司独立董事钱跃竑、肖强、黄蓉的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事及董事会专门委员会委员以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上 市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等规定中对独立董事独立性的相关要求。 江苏浩欧博生物医药股份有限公司董事会 对独立董事独立性自查情况的专项报告 江苏浩欧博生物医药股份有限公司董事会 2025 年 3 月 14 日 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-018 江苏浩欧博生物医药股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 股东大会召开日期：2025年4月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 （一） 股东大会类型和届次 2024 年年度股东大会 召开日期时间：2025 年 4 月 7 日 10 点 00 分 召开地点：公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 4 月 7 日 至 2025 年 4 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25, ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-014 江苏浩欧博生物医药股份有限公司 第三届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 江苏浩欧博生物医药股份有限公司（以下简称"公司"）第三届监事会第十五 次会议于 2025 年 3 月 4 日发出通知，并于 2025 年 3 月 14 日 13 时在公司会议室召 开。本次会议应到监事 3 名，实到监事 3 名，会议由监事会主席焦海云女士主持。 会议符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 1. 审议通过《关于<公司 2024 年年度报告>及其摘要的议案》 监事会认为：公司 2024 年年度报告的编制和审议程序符合相关法律法规及《公 司章程》的规定；公司 2024 年年度报告的内容与格式符合相关规定，公允地反映了 公司 2024 年度的财务状况和经营成果等事项；监事会全体成员保证公司 2024 年年 度报告披露的信息真实、准确、完整，不存在任何虚假记载、误导性陈述 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-013 江苏浩欧博生物医药股份有限公司 第三届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 1. 审议通过《关于<公司 2024 年年度报告>及其摘要的议案》 经审议，董事会认为：《公司 2024 年年度报告》及其摘要的编制和审核程序符 合相关法律法规及《公司章程》的有关规定，能够公允地反映公司报告期内的财务 状况和经营成果。董事会全体成员保证公司 2024 年年度报告披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、 准确性和完整性依法承担法律责任。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《江苏浩 欧博生物医药股份有限公司 2024 年年度报告》及《江苏浩欧博生物医药股份有限 公司 2024 年年度报告摘要》。 本次董事会会议召开前，本议案已经公司董事会审计委员会审议通过。 表决情况：7 票同意，0 票反对，0 票弃权，同意的票数 ...

每股分配比例：每股派发现金红利 0.3 元（含税），不进行资本公积转增股本， 不送红股； 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专用证 券账户中的股份数为基数，具体日期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本扣减公司回购专用证券账户中的 股份数发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将另行公告具 体调整情况； 不会触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》（以下 简称"《科创板股票上市规则》"）第 12.9.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 证券代码：688656 证券简称：浩欧博 公告编号：2025-015 江苏浩欧博生物医药股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二）是否可能触及其他风险警示情形 一、利润分配方案内容 （一）利润分配方案的具体内容 经立信会计师事务所（特殊普通合伙）审计，江苏浩欧博生物医药股份有限公司 （以下简称 ...

Financial Performance - The company's operating revenue for 2024 was CNY 402.34 million, representing a 2.01% increase compared to CNY 394.41 million in 2023[23]. - The net profit attributable to shareholders for 2024 decreased by 22.24% to CNY 36.80 million from CNY 47.33 million in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 35.88 million, down 17.16% from CNY 43.30 million in 2023[24]. - The company's cash flow from operating activities for 2024 was CNY 101.22 million, a decrease of 1.43% compared to CNY 102.69 million in 2023[24]. - Basic earnings per share for 2024 were CNY 0.59, down 21.33% from CNY 0.75 in 2023[25]. - The company's total assets increased by 8.80% to CNY 1,032.80 million at the end of 2024, compared to CNY 949.26 million at the end of 2023[24]. - The company's net assets attributable to shareholders increased by 0.17% to CNY 812.14 million at the end of 2024, compared to CNY 810.73 million at the end of 2023[24]. - The company's overall operating revenue increased by 2.01% despite a challenging economic environment, driven by strong sales in allergy and autoimmune testing product lines[33]. - Net profit decreased by 22.24% year-on-year, primarily due to significant increases in costs associated with new business investments, particularly in desensitization drugs[33]. Dividend Distribution - The company plans to distribute a cash dividend of 3.0 RMB per 10 shares, totaling approximately 18.68 million RMB, which represents 50.75% of the net profit attributable to shareholders for the fiscal year 2024[6]. - In 2023, the company distributed a cash dividend of RMB 0.40 per share, amounting to RMB 24.90 million, which accounted for 52.61% of the net profit attributable to shareholders[174]. - The cumulative cash dividend over the last three accounting years was RMB 62.50 million, with an average net profit of RMB 41.93 million, resulting in a cash dividend ratio of 149.06%[180]. Research and Development - Research and development expenses accounted for 11.50% of operating revenue in 2024, a decrease of 0.42 percentage points from 11.92% in 2023[25]. - The total R&D investment for the year was CNY 4,626.90 million, representing 11.50% of total revenue, a decrease of 0.42 percentage points from the previous year[73]. - The company has established a standardized research program for natural allergen raw materials to ensure batch consistency[69]. - The company has successfully developed core technology platforms for recombinant antigen expression and purification, ensuring consistency in raw materials across different batches[69]. - The company has applied for 8 invention patents and obtained 2, bringing the total number of invention patents to 107[71]. - The company is focusing on enhancing its core technology capabilities with a dedicated team of technical personnel[147]. - The company has made significant investments in research and development to enhance its product offerings in the biopharmaceutical sector[130]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including collaborations and licensing agreements to enhance product offerings[14]. - The company is exploring new technologies in immunoassay methods to improve diagnostic accuracy and efficiency[13]. - The company is actively pursuing international market expansion by developing products suitable for global markets and establishing international marketing teams[134]. - The company aims to consolidate and expand its market share in allergy testing by leveraging its diverse product offerings and high-quality services[134]. - The company is positioned to capitalize on the domestic market's shift towards local alternatives to imported products, enhancing its competitive edge[61]. - The company is expanding its product menu with 35 allergen projects, including 3 mixed allergens and 10 component allergens, with a total investment of $1,707.00 million and $188.43 million invested in the current period[77]. Product Development and Innovation - The company focuses on in vitro diagnostic reagents, kits, and quality control products for various human samples[12]. - The product lines include enzyme-linked immunoassay products, capturing method products, and chemiluminescence products, enhancing sensitivity and speed in testing[13]. - The company has introduced a series of desensitization products under the brand "欧脱克," covering 17 allergens[14]. - The company has developed a comprehensive product menu in the allergy and autoimmune testing fields, effectively breaking the monopoly of imported products[57]. - The company has launched a total of 56 allergen-specific IgE antibody test kits, including tests for total IgE and common food allergens[44]. - The company’s self-immune product line includes 51 different detection items, focusing on specific antibody testing for various autoimmune diseases[46]. - The company aims to replace high-priced imported enzyme-linked immunosorbent assay products with its own chemiluminescence products in the self-immune testing field[46]. Operational Efficiency - The company has upgraded 8 automated production lines to enhance smart manufacturing capabilities, improving efficiency and product quality while reducing labor costs[37]. - The production strategy is based on "sales-driven production" to maintain safety stock levels, with production plans adjusted according to sales forecasts[49]. - The company has established a systematic supplier management mechanism to ensure the stability and quality of its supply chain[47]. - The company emphasizes a strict quality management system, adhering to ISO13485 standards and ensuring full-process quality control from raw material inspection to finished product testing[38]. Risks and Challenges - The company faces risks related to new product development and registration, which typically require over a year for completion, impacting future profitability if not successfully executed[88]. - There is a risk of core technology leakage and loss of key personnel, which could undermine the company's competitive advantage in the market[88]. - The company faces risks related to the potential exclusion of food-specific IgG testing products from medical insurance directories, which could adversely affect sales[91]. - The market for food-specific IgG testing products is limited due to academic controversies, posing a risk to future revenue[91]. - The company is navigating challenges in promoting its new Otuoke series products, which currently can only be sold in designated areas, potentially limiting sales growth[89]. Corporate Governance - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not reported any special arrangements in corporate governance[8]. - The company has established a comprehensive quality management system, ensuring no major product quality issues or disputes during the reporting period[39]. Environmental, Social, and Governance (ESG) - The company emphasizes the integration of ESG principles into its operational management, aiming for sustainable and high-quality development[193]. - The company invested ¥87.76 million in environmental protection measures during the reporting period[196]. - The company is classified as a key pollutant discharge unit and has obtained the necessary discharge permits[197]. - Wastewater generated from production is treated in the company's self-built wastewater treatment station before being discharged into the municipal sewage system[198]. - The company collaborates with qualified third-party waste disposal companies to manage hazardous waste effectively[198].

Financial Performance - Total revenue for 2024 reached RMB 402.31 million, a 2.00% increase compared to RMB 394.41 million in the previous year[3] - Operating profit decreased by 25.88% to RMB 41.39 million from RMB 55.84 million year-on-year[3] - Net profit attributable to shareholders decreased by 22.15% to RMB 36.85 million from RMB 47.33 million in the previous year[3] - Basic earnings per share decreased by 21.33% to RMB 0.59 from RMB 0.75 in the previous year[3] Assets and Equity - Total assets increased by 8.77% to RMB 1,032.50 million from RMB 949.26 million at the beginning of the period[3] - The company's equity attributable to shareholders increased by 0.18% to RMB 812.18 million from RMB 810.73 million at the beginning of the period[3] Business Strategy - The company plans to continue strengthening its main business in allergy and autoimmune diagnostics, with increased investment in new product development and technology[8] - The company aims to optimize supply chain management and enhance cost efficiency to improve core competitiveness and profitability[9] Non-Operating Income - The increase in non-operating income was affected by reduced returns from bank financial products compared to the previous year[10] Financial Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[11]